Common use of Content of Reports Clause in Contracts

Content of Reports. Any Reports provided pursuant to Section 3.3.1 will include at least information regarding: (a) completed activities with respect to the Development of Acquired Antibodies and Products as well as the anticipated Development activities planned in the subsequent [***]; (b) activities with respect to the milestone events described in Section 5.2 including, when such milestone events are expected to be achieved and whether or not such milestone events have been achieved; (c) an updated list of the Acquired Patent Rights or Kiniksa Patent Rights; and (d) the anticipated date and actual date, as applicable, of the First Commercial Sale of each Product in each country of the Territory; provided, however, that after a Product receives Marketing Authorization, the information required in (a) will only need to be provided [***] and will include planned activities for the subsequent [***]. In addition, in order to enable Biogen to prepare its quarterly and annual public disclosures regarding Biogen’s results of operations, on a Product- by-Product basis, upon the earlier of (i) [***] year prior to the anticipated First Commercial Sale of such Product in any country in the Territory, or (ii) the date of Kiniksa’s submission of a Regulatory Filing for a Product in such country, and on a [***] basis thereafter, Kiniksa shall prepare a commercialization report, which report shall include a timeline for achieving First Commercial Sale, a non-binding [***] good faith rolling forecast of Gross Sales and Net Sales of Products in the Field in the Territory, broken down by Calendar Quarters (such forecast, an “Annual [[***]]”). Thereafter, Kiniksa shall provide to Biogen an updated Annual [***] each Calendar Year of the Term.

Content of Reports. Any Reports provided pursuant to Section 3.3.1 4.5.1 (Records; Reports) will include at least information regarding: (a) completed activities with respect to the Development development of Acquired Licensed Antibodies and Licensed Products as well as the anticipated Development development activities planned in the subsequent [***]; (b) activities with respect to the milestone events described in Section 5.2 including9.3 (Development and Regulatory Event Payments), including when such milestone events are expected to be achieved and whether or not such milestone events have been achieved; (c) an updated list of the Acquired Patent Rights or Kiniksa Licensed Patent Rights; and (d) the anticipated date and actual date, as applicable, of the First Commercial Sale of each Licensed Product in each country of the Territory; provided, however, that after a Licensed Product receives Marketing Authorization, the information required in (a) will only need to be provided [***] and will include planned activities for the subsequent [***]. In addition, in order to enable Biogen Kiniksa to prepare its quarterly and annual public disclosures regarding BiogenKiniksa’s results of operations, on a Product- Licensed Product-by-Licensed Product basis, upon the earlier of (i) [***] year prior to the anticipated First Commercial Sale of such Licensed Product in any country in the Territory, or (ii) the date of KiniksaGNE’s submission of a Regulatory Filing BLA for a Licensed Product in such countryany country in the Territory, and on a [***] basis thereafter, Kiniksa GNE shall prepare a commercialization report, which report shall include a non-binding timeline for achieving First Commercial Sale, Sale and a non-binding [***] good faith rolling forecast of Gross Net Sales and Net Sales of Licensed Products in the Field in the Territory, broken down by Calendar Quarters (such forecast, an “Annual [[***]]] Forecast”). Thereafter, Kiniksa GNE shall provide to Biogen Kiniksa an updated Annual [***] Forecast by [***] of each Calendar Year of the Agreement Term.